Abstract:Alzheimer's disease (AD) is a progressive and deleterious neurodegenerative disease, strongly affecting the cognitive functions and memory of seniors worldwide. Around 58% of the affected patients live in low and middle-income countries, with estimates of increasing deaths caused by AD in the coming decade. AD is a multifactor pathology. Mitochondrial function declines in AD brain and is currently emerging as a hallmark of this disease. It has been considered as one of the intracellular processes severely compromised in AD. Many mitochondrial parameters decline already during aging; mitochondrial efficiency for energy production, reactive oxygen species (ROS) metabolism and the de novo synthesis of pyrimidines, to reach an extensive functional failure, concomitant with the onset of neurodegenerative conditions. Besides its impact on cognitive functions, AD is characterized by loss of synapses, extracellular amyloid plaques composed of the amyloid-β peptide (Aβ), and intracellular aggregates of hyperphosphorylated Tau protein, accompanied by drastic sleep disorders, sensory function alterations and pain sensitization. Unfortunately, till date, effective management of AD-related disorders and early, non-invasive AD diagnostic markers are yet to be found. MicroRNAs (miRNAs) are small non-coding nucleic acids that regulate key signaling pathway(s) in various disease conditions. About 70% of experimentally detectable miRNAs are expressed in the brain where they regulate neurite outgrowth, dendritic spine morphology, and synaptic plasticity. Increasing studies suggest that miRNAs are intimately involved in synaptic function and specific signals during memory formation. This has been the pivotal key for considering miRNAs crucial molecules to be studied in AD. MicroRNAs dysfunctions are increasingly acknowledged as a pivotal contributor in AD via deregulating genes involved in AD pathogenesis. Moreover, miRNAs have been proved to control pain sensitization processes and regulate circadian clock system that affects the sleep process. Interestingly, the differential expression of miRNA panels implies their emerging potential as diagnostic AD biomarkers. In this review, we will present an updated analysis of miRNAs role in regulating signaling processes that are involved in AD-related pathologies. We will discuss the current challenges against wider use of miRNAs and the future promising capabilities of miRNAs as diagnostic and therapeutic means for better management of AD.

MicroRNAs and synapse turnover in Alzheimer's disease

Progress in molecular mechanisms of β-amyloid peptides in alzheimer's disease

MicroRNAs: Pioneering Regulators in Alzheimer’s Disease Pathogenesis, Diagnosis, and Therapy

MicroRNAs: pioneering regulators in Alzheimer's disease pathogenesis, diagnosis, and therapy

Targeting the Synapse in Alzheimer’s Disease

Transcriptomics study of neurodegenerative disease: emphasis on synaptic dysfunction mechanism in Alzheimer's disease.

The Regulation of Micrornas in Alzheimer's Disease

MicroRNAs as Potential Orchestrators of Alzheimer's Disease-Related Pathologies: Insights on Current Status and Future Possibilities

Molecular Mechanisms of ER Stress and UPR in the Pathogenesis of Alzheimer’s Disease

The synapse as a treatment avenue for Alzheimer’s Disease

Deciphering the role of miRNAs in Alzheimer's disease: Predictive targeting and pathway modulation - A systematic review

Insights into the Role of microRNAs as Clinical Tools for Diagnosis, Prognosis, and as Therapeutic Targets in Alzheimer's Disease

MicroRNAs in Alzheimer’s Disease: Diagnostic Markers or Therapeutic Agents?

The Role Of Micrornas In Alzheimer'S Disease And Their Therapeutic Potentials

Altered synaptic plasticity at hippocampal CA1-CA3 synapses in Alzheimer's disease: integration of amyloid precursor protein intracellular domain and amyloid beta effects into computational models

Gene expression parallels synaptic excitability and plasticity changes in Alzheimer’s disease

Oligomeric Aβ-induced Synaptic Dysfunction in Alzheimer’s Disease

Alterations in Micro RNA-Messenger RNA (Mirna-Mrna) Coupled Signaling Networks in Sporadic Alzheimer's Disease (AD) Hippocampal CA1

Dysregulation of Neuronal Protein Synthesis in Alzheimer’s Disease

Targeting Microglia-Synapse Interactions in Alzheimer's Disease

Anti-microRNAs As Novel Therapeutic Agents in the Clinical Management of Alzheimer's Disease